Trustmark National Bank Trust Department Sells 3,007 Shares of Sanofi (SNY)
Trustmark National Bank Trust Department lowered its stake in shares of Sanofi (NYSE:SNY) by 25.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,880 shares of the company’s stock after selling 3,007 shares during the quarter. Trustmark National Bank Trust Department’s holdings in Sanofi were worth $442,000 at the end of the most recent quarter.
A number of other institutional investors also recently made changes to their positions in SNY. Parallel Advisors LLC grew its stake in Sanofi by 42.5% in the 2nd quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock valued at $139,000 after purchasing an additional 875 shares during the period. YorkBridge Wealth Partners LLC grew its stake in Sanofi by 33.7% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 3,076 shares of the company’s stock valued at $147,000 after purchasing an additional 776 shares during the period. Bronfman E.L. Rothschild L.P. grew its stake in Sanofi by 142.8% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,567 shares of the company’s stock valued at $171,000 after purchasing an additional 2,098 shares during the period. Toronto Dominion Bank grew its stake in Sanofi by 4.6% in the 2nd quarter. Toronto Dominion Bank now owns 4,054 shares of the company’s stock valued at $195,000 after purchasing an additional 180 shares during the period. Finally, Mraz Amerine & Associates Inc. bought a new position in Sanofi in the 3rd quarter valued at $204,000. Institutional investors and hedge funds own 9.30% of the company’s stock.
Shares of Sanofi (NYSE:SNY) traded up $0.73 during trading hours on Friday, reaching $46.10. The company’s stock had a trading volume of 523,759 shares, compared to its average volume of 1,058,229. The company has a market cap of $116,241.52, a P/E ratio of 14.54, a PEG ratio of 2.54 and a beta of 0.88. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.59 and a quick ratio of 1.16. Sanofi has a 52-week low of $38.45 and a 52-week high of $50.65.
SNY has been the subject of a number of recent analyst reports. upgraded Sanofi from a “reduce” rating to a “hold” rating in a research note on Wednesday, August 30th. J P Morgan Chase & Co restated a “neutral” rating on shares of Sanofi in a research note on Friday, September 15th. Zacks Investment Research downgraded Sanofi from a “hold” rating to a “strong sell” rating in a research note on Friday, October 6th. Barclays PLC upgraded Sanofi from an “underweight” rating to an “equal weight” rating in a research note on Wednesday, November 15th. Finally, Argus restated a “buy” rating and issued a $55.00 price objective on shares of Sanofi in a research note on Friday, September 1st. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $53.50.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with Analyst Ratings Network's FREE daily email newsletter.